Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Co.'s primary product candidate, vonoprazan, is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has shown effects and has demonstrated clinical results as an agent in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of H. pylori infection. We show 19 historical shares outstanding datapoints in our PHAT shares outstanding history coverage, used to compute PHAT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PHAT market cap history over the course of time is important for investors
interested in comparing PHAT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PHAT versus a peer is one thing; comparing
PHAT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PHAT can fluctuate over the course of history.
With this page we aim to empower investors researching PHAT by allowing them to research the PHAT market cap history. |
Free PHAT Email Alerts:
Video: The Importance of Market Cap
